论文部分内容阅读
目的:探讨可溶性细胞间黏附分子-1(sICAM-1)在原发性肝癌(PHC)患者血清中的水平及其与肝纤维化的关系。方法:采用ELISA方法测定45例PHC患者、30例良性肿瘤患者和35例健康查体者血清sICAM-1和肝纤维化四项(PCⅢ、Ⅳ-C、LN、HA)水平,并分析sICAM-1与肝纤维化之间的关系。结果:PHC组血清sICAM-1和肝纤维化四项(PCⅢ、Ⅳ-C、LN、HA)水平均显著高于良性肿瘤组和正常对照组,相比较有显著性差异(P<0.05);而良性肿瘤组和正常对照组各指标比较差异无统计学意义(P>0.05);血清sICAM-1含量与PCⅢ、Ⅳ-C、LN、HA含量呈显著正相关性(r=0.683、0.575、0.573、0.539,P<0.05)。结论:检测血清sICAM-1的水平对判定PHC患者的病情、为肝癌的早期诊断和治疗有着重要的临床意义。
Objective: To investigate the serum level of soluble intercellular adhesion molecule-1 (sICAM-1) in primary liver cancer (PHC) patients and its relationship with hepatic fibrosis. METHODS: Serum sICAM-1 and four liver fibrosis (PCIII, IV-C, LN, HA) levels in 45 patients with PHC, 30 patients with benign tumors, and 35 healthy subjects were determined by ELISA and analyzed for sICAM- 1 Relationship with liver fibrosis. Results: Serum sICAM-1 and four liver fibrosis (PCIII, IV-C, LN, HA) levels in PHC group were significantly higher than those in benign tumor group and normal control group, with significant differences (P<0.05). However, there was no significant difference in the indexes between the benign tumor group and the normal control group (P>0.05). There was a significant positive correlation between the serum sICAM-1 content and the levels of PCIII, IV-C, LN and HA (r=0.683, 0.575). 0.573, 0.539, P<0.05). Conclusion: The detection of serum sICAM-1 level has important clinical significance for judging the condition of PHC patients and for the early diagnosis and treatment of liver cancer.